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B-cell precursors (BCP) arise from hematopoietic stem cells in bone marrow (BM).
Identification and characterization of the different BCP subsets has contributed to the
understanding of normal B-cell development. BCP first rearrange their immunoglobulin
(Ig) heavy chain (IGH) genes to form the pre-B-cell receptor (pre-BCR) complex
together with surrogate light chains. Appropriate signaling via this pre-BCR complex
is followed by rearrangement of the Ig light chain genes, resulting in the formation,
and selection of functional BCR molecules. Consecutive production, expression, and
functional selection of the pre-BCR and BCR complexes guide the BCP differentiation
process that coincides with corresponding immunophenotypic changes. We studied
BCP differentiation in human BM samples from healthy controls and patients with
a known genetic defect in V(D)J recombination or pre-BCR signaling to unravel
normal immunophenotypic changes and to determine the effect of differentiation blocks
caused by the specific genetic defects. Accordingly, we designed a 10-color antibody
panel to study human BCP development in BM by flow cytometry, which allows
identification of classical preB-I, preB-II, and mature B-cells as defined via BCR-related
markers with further characterization by additional markers. We observed heterogeneous
phenotypes associated with more than one B-cell maturation pathway, particularly
for the preB-I and preB-II stages in which V(D)J recombination takes place, with
asynchronous marker expression patterns. Next Generation Sequencing of complete
IGH gene rearrangements in sorted BCP subsets unraveled their rearrangement status,
indicating that BCP differentiation does not follow a single linear pathway. In conclusion,
B-cell development in human BM is not a linear process, but a rather complex
network of parallel pathways dictated by V(D)J-recombination-driven checkpoints and
pre-BCR/BCR mediated-signaling occurring during B-cell production and selection. It
can also be described as asynchronous, because precursor B-cells do not differentiate
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as full population between the different stages, but rather transit as a continuum, which
seems influenced (in part) by V-D-J recombination-driven checkpoints.
Keywords: next generation sequence (NGS), immunoglobulin repertoire, bone marrow, flow cytometry,
precursor B-cell
INTRODUCTION
B cells arise from hematopoietic stem cells in bone marrow
(BM) and develop in a stepwise manner (1, 2). Identification and
characterization of the different B-cell precursor (BCP) subsets
contributes to the understanding of normal B-cell development
(3, 4). Currently, it is accepted that expression of the PAX5
transcription factor triggers commitment to the B-cell lineage
through the expression of B-cell specific genes such as CD79a
(or Igα) and CD19, while suppressing B-lineage inappropriate
genes. Since cytoplasmic expression of CD79a (cyCD79a) is
one of the first signs of B-cell lineage commitment, human
cyCD79a+ CD19- cells are defined as pro-B cells, followed
by CD19 expression in pre-B-I cells. During this stage, V-D-J
recombination of the immunoglobulin (Ig) heavy chain (IGH)
locus is initiated by the recombination activating genes (RAG1
and RAG2) (5–11). If this rearrangement process results in
a functional protein, Igµ heavy chain is expressed in the
cytoplasm (cyIgµ), which defines the pre-BII-stage. Whenever
rearrangement of the first allele does not result in a productive
Igµ molecule, the second allele will be rearranged. Igµ is
expressed on the cell membrane together with the surrogate
light chains λ14.1 and VpreB as pre-B-cell receptor (pre-BCR)
(12, 13). Pre-BCR signaling triggers a cascade of events including
downregulation of the recombination machinery to ensure allelic
exclusion and subsequent proliferation, followed by opening
of the Ig light chain (IGL) locus, which is being rearranged
under the influence of a second expression wave of RAG1
and RAG2 (10, 14). After successful IGL rearrangement, a
functional BCR in the form of a complete IgM molecule is
expressed on the cell surface membrane, defining progression to
the immature B-lymphocyte stage. Subsequent IgD expression
on the plasma membrane of IgM+ immature B-cell leads to
the differentiation into mature naive B-lymphocytes, which
are released from BM to peripheral blood (PB). In addition
to the above described changes in rearrangement status and
expression of Ig molecules, BCP undergo also other maturation-
associated immunophenotypic changes. Whereas, Pro-B cells
express stem cell markers such as CD34 and CD10, later stages
start to express B-cell specific markers such as CD19 and CD20.
Additionally, cells that are in their rearrangement process express
TdT in two waves, one during the IGH gene rearrangements
and another during the IGL gene rearrangement which ensures
junctional diversity by random addition of non-templated
nucleotides at the joining sites of the V, D, and J genes.
Expression of these markers and the different variants of the
immunoglobulin (BCR) complex-molecules can be studied with
flow-cytometry (15).
Most knowledge about B cell development in BM came
from mouse studies; however, detailed insight into normal
human BCP development is important to identify and unravel
pathophysiological processes in hematological malignancies and
primary immunodeficiencies (PID), caused by genetic defects
(16). In turn, BCP analysis in genetically-defined PID can help
elucidating the role of specific genes in BCP development (13,
17), because absence (or dysfunction) of essential proteins cause
a full or incomplete block ofmaturation at specific developmental
stages (18–20).
Here, we studied BCP differentiation in BM from both healthy
controls and patients with a well-defined genetic defect in
V(D)J recombination or pre-BCR signaling, to further unravel
the normal immunophenotypic profiles of BM BCP at distinct
stages of maturation and to determine the type of differentiation
blockades caused by specific genetic defects. In multiple cycles of
design, testing, evaluation, and redesign, we developed a 10-color
antibody combination and applied novel data analysis strategies
based on multivariate (principal component and viSNE) analysis
(21) that allowed more detailed characterization of previously
described BCP populations. This 10-color antibody combination
was first validated against a conventional 4-color panel (7, 15,
18, 22). Secondly, we analyzed Ig gene rearrangement status and
the gating strategy based on BCR-associated markers (cyCD79a,
cyIgµ, IgM, IgD, CD19) was compared with gating based on
membrane markers such as CD10 and CD20, as also done in the
literature (7, 23–25). Gating based on BCR-associated markers
allowed us to define the crucial steps of B cell development
better than gating based on other non-BCR-associated surface
markers alone, while intracellular markers emerged as essential
to adequately delineate BCP development.
MATERIALS AND METHODS
Bone Marrow Samples
BM samples from healthy controls were left over samples from
healthy children who donated BM for transplantation into a
diseased sibling or were collected from patients that had a
BM biopsy to rule out other diseases than lymphoid PID. The
latter BM samples were considered to be normal when no
malignant cells were detected in combination with a normal BCP
differentiation pattern upon standard diagnostic testing. Patient
BM samples were collected for PID-diagnostics. Both normal BM
samples and patient BM samples in this study were obtained with
informed consent according to the guidelines of the local medical
ethics committee of the Erasmus MC (MEC-2013-026) and the
LUMC (P08.001).
Flow Cytometric Immunophenotyping and
Repertoire Analysis of Bone Marrow
Flow cytometric immunophenotyping of BM samples was
performed on a LSR Fortessa (BD Biosciences, San Jose, CA)
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with instrument setting according to EuroFlow SOP (26).
Following the EuroFlow bulk-lysis SOP (26, 27), cells were
stained for surface membrane (sm) and intracellular markers
in two consecutive steps. The following surface stainings
-fluorochrome conjugate (clone)- were used: IgM-BV510
(MHM-88) CD38-BV605 (HIT2) and CD20-PB (2H7) were
all from Biolegend (San Diego, CA); CD34-APC (8G12)
and IgD-PeCF594 (IA6) were both from BD Biosciences);
CD19-PC7 (J3-119) was purchased from Beckman Coulter
(Fullerton, CA); and CD10-APC-C750 (HI10a) was obtained
from Cytognos (Salamanca, Spain). Sustained cells were
fixed and permeabilized using the Fix&Perm reagent kit
(An der Grub, Vienna, Austria) according to manufacturer’s
instructions, and further stained for intracellular markers:
IgM-PerCPcy5.5 (MHM-88) from Biolegend; TdT-FITC (HT6)
purchased from (Supertechs, Rockville, MD); and CD79a-PE
(HM47) purchased from Beckman Coulter) (see Table 1 for
complete panel).
Patient BM samples were analyzed in parallel with a
diagnostic 4-color panel as previously described (7, 18),
for comparison of the new 10-color panel to the 4-color
diagnostic panel (gold standard). Based on the 4-color
protocol the main precursor B-cell populations were
defined as follows: pro-B-cells as CD22+CD19−; pre-B-I
cells as CD19+cyIgµ−, pre-B-II cells as CD19+cyIgµ+IgM−;
immature cells as CD19+IgM+IgD− and CD19+IgM+IgD+.
For calculation the composition of the precursor B-cell
compartment mature B-cells are excluded, because mature
B-cells can also arise from peripheral contamination. An
overview of the antibodies used in all panels can be found
in Table 1.
For data was analysis with Infinicyt (Version 1.8, Cytognos)
and Cytobank (Cytobank, Inc, Santa Clara, CA, USA) software
programs were used. Principle component analysis was
performed with the Infinicyt software. This method calculates
the most discriminating projections based on selected
parameters, into a single Automated Population Separator
(APS) bi-dimensional graph. Multiple APS graphs (APS1,
APS2 etc.) can be generated, depending on which parameters
contribute more or less to the principle components on the
X-axis and Y-axis. ViSNE projection (21) was calculated using
Cytobank (Cytobank, Inc, Santa Clara, CA, USA) (28). This
method generates a 2D dotplot in which the X- and Y-axis
are defined by virtual parameters called tSNE1 and tSNE2,
in which all events are projected integrating information
on all selected parameters. In a viSNE plot the distance of
one event to other events represents how similar events
are, with the most similar events plotting closest to each
other (21).
For repertoire analysis, two BM samples without malignant
cells and with normal BCP differentiation (determined with
standard diagnostic testing) were enriched for B cells using
a RosetteSepp human B-cell enrichment cocktail (Stem
cell Technologies, Vancouver, Canada) according to the
manufacturer’s instructions, as described elsewhere (29).
Subsequently, the B-cell enriched samples were frozen in liquid
nitrogen and thawed prior to sorting. Sorting was done with
the same 10-color antibody combinations as described above
on an FACS Aria-III flow cytometer (BD Biosciences). After
sorting, cells were washed and DNA was isolated using a
direct lysis procedure as described elsewhere (30). From this
DNA, IGH rearrangements were amplified in a 2-step PCR
and sequenced by NGS. IGH rearrangements were amplified
(35 cycles) using the forward VH1-6 FR2 and reverse JH
consensus EuroClonality/BIOMED-2 primers, extended with
Illumina P5 and P7 adapter sequence (31). Subsequently, PCR
products were purified by gel extraction (Qiagen, Valencia,
CA), followed by a nested PCR reaction (12 cycles) to include
the sample-specific indices and Illumina sequencing adapters
using primers from the Illumina TruSeq Custom Amplicon
Index Kit (Illumina, San Diego, CA). The final PCR product
concentration was measured using the Quant-it Picogreen
dsDNA assay (Invitrogen, Carlsbad, CA). The libraries were
analyzed by NGS (221 bp paired-end) on the MiSeq platform
(Illumina, San Diego, CA, USA) with use of an Illumina MiSeq
Reagent Kit V3, according to the manufacturer’s protocol
(Illumina, San Diego, CA, USA). Paired sequences were
aligned using paired-end read merger (PEAR) (32), and the
fastq files were converted to fasta files (33). Subsequently,
the sequences were trimmed to remove the primer sequence
and uploaded in IMGT/High-V-Quest (34); subsequently,
the IMGT output files were analyzed using the ARGalaxy
tool (https://bioinf-galaxian.erasmusmc.nl/argalaxy) (35). For
analysis only a single sequence per clone (defined as same V
gene, same J gene and the nucleotide sequence of the CDR3
region) were included. In-frame IGH rearrangements were
defined to have an in-frame rearrangement without a stop
codon. Unproductive IGH rearrangements were either out-
of-frame rearrangements or in-frame rearrangements with a
stop codon.
TABLE 1 | Composition and technical information on reagents of the 10-color EuroFlow BCP tube.
Fluorochrome PB BV510 BV605 FITC PE PE-CF594 PerCP-Cy5,5 PE-Cy7 APC Alexa750
Target CD20 IgM CD38 TdT CD79a IgD cyIgM CD19 CD34 CD10
clone 2H7 MHM-88 HIT2 HT6 HM47 IA6 MHM-88 J3-119 8G12 HI10a
Volsume
(undiluted)
1 µl 1.3 µl 1 µl 10 µl 5 µl 3 µl 2.5 µl 5 µl 2.5 µl 5 µl
Shaded fields indicate intracellular markers.
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FIGURE 1 | Major BCP subsets in human bone marrow. (A) Schematic representation of the BCP subsets in human bone marrow, the green bars indicate when
recombination processes take place. (B) Population definition based on BCR-related markers. All cyCD79a expressing cells are considered BCP or B cells. Pro-B
cells are defined as CD19- TdT+, pre-BI cells are defined as CD19+ cyIgµ- IgM-, pre-BII cells are defined as CD19+ cyIgµ+ IgM-, immature B cells are defined as
CD19+ IgM+ IgD- and mature B cells are defined as CD19+ IgM+ IgD+. (C) BCP subset distribution in the same sample that was acquired in parallel with two
different panels. Population definition was in both cases done as indicated above.
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RESULTS
Subset Definition Based on
BCR-Associated Markers Is Consistent
Between Different Panels
To study human BM, we designed and validated a 10-color
flowcytometry antibody combination to be stained in a single
tube (Table 1), to make optimal use of available material and
integrate information about both intracellular and extracellular
markers on each individual cell. This 10-color tube was
tested against a previously validated 4-color diagnostic panel
(7, 18) using BM samples from healthy controls and PID
patients. B cells and BCP were defined as cyCD79a+. The five
major B-cell populations (pro-B, pre-BI, preB-II, immature and
mature B cells) (Figure 1A) were gated based on the staining
profiles for the BCR-associated markers CD19, nTdT, cyIgµ,
IgM, and IgD (Figure 1B and Supplementary Material), as
defined by the previously observed subset distribution with
the 4-color panel used as gold standard. Since IgMD+ cells
(mature B cells) can also be detected in peripheral blood
(PB), they were not considered as a formal BCP stage. In ten
independent (n = 4 controls and 6 patients) samples both
panels revealed the same precursor B-cell subset distribution,
as illustrated by three representative cases in Figure 1C: one
of normal BCP development, a RAG deficient patient and
a BTK deficient patient. This indicates that gating based on
BCR-associated markers is consistent between both panels and
gives comparable results in both healthy controls and PID
patients with defects in BCR signaling or V(D)J recombination
(Figure 1C).
B-Cell Populations Defined Based on
BCR-Associated Markers Only Show
Heterogeneous Intra-Population
Phenotypes
Based on BCR-associated markers only (cyCD79a, CD19,
cyIgµ, IgM, and IgD), 4 distinct subsets of BCP were
identified/defined as described above. Further analysis of
the expression profiles for other markers (i.e. TdT, CD34,
CD10, CD20, and CD38) within these four B-cell populations
showed highly heterogeneous patterns, particularly within pre-
BI and pre-BII BCP (Figure 2A). Thus, pre-BI BCP were
mainly TdT+ and CD34+, but some cells had lost one or
both markers, while, at the same time, they were CD10+
and CD20- ruling out they could be unswitched memory
B-cells. Similarly heterogeneous patterns of expression were
observed for CD10 and CD38 (most cells being positive
but a minority negative) and CD20 (most cells CD20- but
some were CD20+), pointing out the existence of multiple
subsets of pre-BI cells (Figure 2A). In turn, pre-BII cells,
were cyIgµ-positive while mostly negative for CD34 and
TdT, but with some CD34+ and TdT+ pre-B-II cells. CD20
expression was highly heterogeneous within this population
with progressively more CD20 molecules per cell (Figure 2A).
Multivariate (e.g., viSNE) analysis confirmed the presence of
minor subsets of TdT−CD34− pre-BI B-cells and CD34+TdT+
pre-BII cells, both populations showing progressively higher
expression levels of CD20, similarly to immature B-lymphocytes
(Figure 2B).
Asynchronous Expression of
Non-BCR-Associated Markers in BCP
Stages Defined by BCR-Associated
Patterns
In order to gain further insight into the relationship between
the pattern of expression of non-Ig related markers and cyIgµ,
we compared BM pre-BI and pre-BII cells from controls to
patients with RAG-deficiency and BTK-deficiency. As described
above a fraction of all pre-BI cells in controls, loses CD34
and/or TdT expression, and some upregulate CD20 (Figure 3).
In RAG-deficient patient, TdT expression remains intact, but
loss of CD34 together with some upregulation of CD20 was
observed. Thus, it appears that BCP can lose CD34 and
upregulate CD20 in the absence of a functionally rearranged
heavy chain while they do not loose TdT. In BTK-deficiency
a similar profile was observed. In addition, within the pre-
BII BCP of controls and BTK-deficient patients, some cells
retained CD34 and/or TdT expression, although they already
expressed cyIgµ. Since RAG deficient patients do not have pre-
BII cells, we could not compare this subset for these patients.
Altogether, there results point out the existence of different
kinetics of expression of BCR-associated and other non-BCR-
related markers during normal B-cell maturation. Additionally,
RAG or BTK deficient cells can lose CD34 expression, without
downregulating TdT.
Dissection of Multiple BCP Maturation
Pathways in BM
Multivariate analysis of normal BM BCP based on all markers
evaluated simultaneously revealed the existence of up to
three (parallel) distinct maturation pathways, where the BCR-
associated cyIgM and CD20 represent the major discriminating
markers (Supplemental Figure 1). Based on a data set of 5
healthy control BM samples, a reference BM profile was built
using the APS1 view –Principal Component (PC) 1 vs. PC2-
of the in Infinicyt software (36) (Figure 4A), after plotting the
2SD lines corresponding to each reference population of normal
BCP. Once this reference profile has been built, BCP events
from a sixth, independent healthy donor was plotted against
it (Figure 4B), the events neatly falling within the ranges of
the other 5 healthy controls BM samples. In contrast, when
BM BCP from a patient with RAG-deficiency and another
child with BTK-deficiency were plotted against the reference
profile, profiles with a clear blockade appeared with most cells
exclusively present within the first maturation pathway. In
the BTK deficient patient, a small fraction of the BCP cells
reached the pre-B-II stage (Figure 4C). Furthermore, in this
representation, some patient cells fell outside the 2SD lines of
both pre-BI and pre-BII suggesting the existence of aberrant
phenotypic profiles.
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FIGURE 2 | Heterogeneity within BCP subsets. (A) Dotplots of a representative normal bone marrow sample, showing all cyCD79a+ B cells in bone marrow.
Populations of interest are highlighted in a different color: pro-B cells in pink, pre-B-I cells in green, pre-B-II cells in blue, immature cells in orange. (B) Results of a
viSNE analysis of individual B-cell precursor subsets, represented by tSNE-1 vs. tSNE-2 plots. The color scale represents the intensity of the stain for individual
markers: TdT, CD34, CD20, CD10, and CD38.
IGH Gene Rearrangement Profile of BCP at
the pre-BI and pre-BII Stage Showing
Distinct Patterns of Expression of CD34
and TdT
When we focused on the cells that were neither within the 2SD
interval of the pre-BI cells nor in the 2SD interval of pre-BII cells,
we found that they are present in normal BCP differentiation
(between 1 and 3% of all BCP cells), although not as many as in
the patient samples (Figure 5A). These cells are defined as pre-
BI or pre-BII based on the absence or presence of cyIgµ, but
the expression of TdT, CD34, CD10, and CD20 is asynchronous
with their cyIgµ status (Figure 5B). We can divide the pre-
BI cells in true pre-BI cells that are CD19+ cyIgµ- CD34+
TdT+ (pre-BI+/+) and another, more heterogeneous group that
is CD19+ cyIgµ- but where CD34 and or TdT expression is
negative (pre-BI–/–). These cells are not switched memory B
cells coming from peripheral blood, because they all express
both CD10 and CD38. The same split can be made within the
pre-BII cells, dividing them in pre-BII cells that are CD19+
cyIgµ+ CD34− TdT− (pre-BII–/–) and a heterogeneous group
that is CD19+, cyIgµ+ but that still have CD34, TdT or
both these markers (pre-BII+/+). In the APS views that are
based on all BCPs, these cells end up between pre-BI and pre-
BII. If we create an APS view of only the pre-BI and pre-BII
stages, we can examine how heterogeneous these populations
are (Figures 5C,D).
Rearrangement Status Classifies the
Intermediate Stages
To further dissect this, we sorted the pre-B populations into
four populations: pre-BI +/+ (CD19+ cyIgµ- CD34+ TdT+),
pre-BI–/– (CD19+ cyIgµ− CD34- TdT−), pre-BII–/– (CD19+
cyIgµ+ CD34− TdT−) and pre-BII+/+ (CD19+ cyIgµ+
CD34+ TdT+). We isolated DNA from these subsets and
sequenced complete IGH rearrangements using next-generation
sequencing. We found that in the pre-BI+/+ cells, the majority
of complete rearrangements is non-productive with an in-frame:
non-productive ratio of 1:9, which is in line with the observation
that these cells do not express cyIgu, yet (Figure 5E). In the pre-
BII–/– cells, the in-frame: non-productive ratio is 4:1, with∼80%
of rearrangements in frame, which is in line with the observation
that these cells all express cyIgu. In the pre-BI–/– population,
the in-frame: non-productive ratio is 3:1, and in the pre-BII+/+
population, this ratio is also 3:1. In these populations, the relative
amount of in-frame complete rearrangements is approximately
the same, however, in one population the cells do not express
cyIgu, whereas they do in the other populations. This indicates
that in the pre-BI–/– cells in-frame rearrangements are present,
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FIGURE 3 | pre-BI and pre-BII marker expression in control and patient samples. (A) Dot plots representing pre-BI cells from a control sample, and two patient
samples, indicating the uncoupling of expression of cyIgµ and surface markers like CD34, CD20, and CD10. In both the control and the patients, cells without cyIgµ
can lose CD34 expression and gain CD20 expression. (B) Dot plots representing pre-BII cells from a control sample, and two patient samples. In both the control and
the patients, cells with cyIgµ expression can still express CD34 and TdT, and CD20 expression is heterogeneous.
but they are either not productive (i.e., not leading to a functional
protein) or they are not (yet) expressed. The pre-BII+/+ already
express cyIgu, but did not yet downregulate CD34 and TdT.
In addition, we analyzed the CDR3 lengths of the productive
rearrangements as well as proportion of IGH CDR3s with ≥3,
2, 1, or 0 positive charges (Figures 5F,G). The CDR3 lengths
of productive rearrangements of pre-B-I–/– cells were longer
than the productive rearrangements of pre-B-I+/+ and pre-B-II
cells, which could be explained by a lower number of nucleotide
deletions. The proportions of IGH CDR3 charges did not differ
between the four subpopulations.
DISCUSSION
In this study, we designed and validated a 10-color flow
cytometry panel, to study human BCP development in BM of
immune deficient patients at crucial developmental thresholds
in more detail than was done previously. In our standardized
measurements, we could reliably gate populations according
to BCR-related markers. This allowed us to superimpose PID
samples over healthy controls and describe the deviations from
normal development as found in patients. Unexpectedly, when
we included information from additional (non-BCR) markers,
we found heterogeneity, especially within the preB-I and preB-
II populations, during which V(D)J recombination takes place
with expression of surface markers that seem asynchronous
to the expression of cyIgµ. NGS analysis of complete IGH
rearrangements in sorted populations was used to determine the
rearrangement status at the DNA level.
We showed that BCR-related marker based population
definition is consistent over samples and different panels,
but this results in heterogeneous populations when other
markers, like CD34, TdT, and CD20 are considered. Upon
more in-depth study of expression patterns of these markers,
we found that in some specific populations, expression
of these markers is asynchronous to the process of BCR-
formation. This effect is more visible in patients with defects
in V(D)J-recombination. Specifically, we found that CD20
can be upregulated in the absence of cyIgµ expression and
that cells can lose TdT expression and CD34 expression
without having expression of heavy chain protein in
the cytoplasm.
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FIGURE 4 | Supervised APS view of BCP populations in healthy bone marrow (n = 5) indicated by lines at 2SD intervals. (A) BCP populations in a pool of 5 healthy
bone marrow samples that were used to create the APS view. Lines indicate the 2 SD range of each population, dot indicate individual cells. The different populations
are indicated by the different colors. (B) 2 SD lines of BCP populations derived from a pool of 5 healthy donors, dots indicate total BCP from a sixth healthy donor, a
RAG deficient patient and a BTK deficient patient, plotted against the reference pool. (C) Bars indicate the BCP subset distribution of each sample, compared to age
matched controls (<5 years).
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FIGURE 5 | Further dissection of the BCP compartment. (A) APS views indicating the cells that are outside the 2SD lines of the pre-B-I and pre-B-II populations of
healthy controls. (B) Expression of CD34, TdT, CD10, and CD20 within cyIgµ- (in green) and cyIgµ+ cells. All cells here are CD19+ CD10+ CD38+ indicating that
they are bone marrow derived B cells. (C) APS views indicating the cells that are outside the 2SD lines of the pre-BI and pre-BII populations of healthy controls, color
coded as in B. (D) APS view supervised on pre-BI and pre-BII cells, separating the transitioning pre-B cells further. (E) Distribution of in-frame and out-of-frame
DNA-rearrangements in sorted pre-B subpopulations. (F) CDR3 length of productive rearrangements of the four sorted pre-B-I and pre-B-II populations. (G) The
proportion of CDR3 regions with ≥3, 2, 1, or 0 positive charges.
We combined the population-gating based strategy that is
often used in flow cytometry with principle component analysis.
We showed that the BCP populations seem to overlap, indicating
a continuous process rather that a step-wise differentiation. This
is in line with asynchronous marker expression that we see
between surface markers e.g. each cell seems to up-and-down
regulate its phenotype markers at its own pace. Even more, some
phenotype markers that were previously thought to be V(D)J-
recombination dependent, seem to progress even in the absence
of cyIgµ expression, as indicated by loss of CD34 and gain of
CD20 in patients with genetic defects in V(D)J-recombination.
Some of the cellular phenotypes that we found in controls
are more common in genetically defined patient samples. This
indicates that, even though cells cannot successfully rearrange
their IgH-locus, as is the case in RAG deficiency (10, 37),
they will still lose CD34 expression as if they are progressing
to the next stage. In addition to that, we found that CD20
expression is gradually increasing over the course of several
stages. However, CD20 expression is heterogeneous in many
populations. Especially in patient samples, we often detected
high CD20 expression in populations that were assumed to
be early in B-cell differentiation. Even though the exact role
of CD20 on B cells is not found yet, it is still a useful
marker indicating B-cell development and if highly expressed in
combination with loss of CD10 and CD38, indicating maturity
of the B cells. CD20 expression does not seem to be related
with BCR-rearrangement.
Both in PID patients and in control samples, we
identified cells outside the reference borders of the defined
populations (e.g., pre-BI and pre-BII) in the APS plots,
although the cell numbers were much lower in control
samples. Especially in the RAG deficient patient this is
striking, because it seems as if some cells can progress in
surface marker expression by expressing CD20 and loosing
CD34, without having a functionally rearranged heavy chain.
This further supports the idea that expression of CD20
and CD34 is not in all cells strictly linked to IGH gene
rearrangement status.
To further dissect this, we sorted preB-I and preB-II
cells and further divided these populations based on their
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CD34 and TdT expression. DNA extracted from these cell
populations was used to study complete IGH-rearrangements
using NGS. In preB-I+/+ cells we showed that close to 90%
of detectable IGH gene rearrangements are non-productive.
Since these cells do not express cyIgu yet, we hypothesize
that these cells have not yet obtained an in-frame IGH
rearrangement, and thus they still express CD34 and TdT. In
preB-II cells that are CD34- TdT-, around 75% of detectable
IGH rearrangements were in-frame. These cells all express cyIgu,
and some have an non-productive rearrangement on one allele
combined with an in-frame rearrangement on the second allele,
which explains the 25% of non-productive rearrangements in
this population. The preB-II +/+ cells also contain ∼75%
of in-frame rearrangements. Possibly, these cells have only
just completed their in-frame rearrangement, starting already
expressing cyIgu but still need to downregulate CD34 and TdT.
However, our data is not sufficient to conclude this. Also, we
detected around 75% in-frame rearrangements in preB-I–/–
cells. These cells have an in frame IGH rearrangement at
the DNA level, but they do not (yet?) express cyIgu protein.
To further investigate this, single-cell analysis on DNA, RNA
and protein level might give further insight in how and why
V(D)J recombination status and phenotypic marker expression
are linked.
In conclusion, we have designed and validated a standardized
10-color staining and analytical tools for the analysis of BCP
compartment in human BM. Our data indicate that BCP
differentiation is not a single linear differentiation pathway,
but rather a complex process of V(D)J recombination-driven
checkpoints, divergence, parallel pathways and convergence
to form a unique and functional BCR. The data also
support the notion that B cell maturation is asynchronous,
implying that precursor B-cells do not differentiate as
full population between the different stages, but rather
transit as a continuum, which can be influenced in part
by V(D)J recombination-driven checkpoints. Due to this
continuum, small populations of cells are captured as they
transit between stages and, thus, have intermediate patterns
of marker expression. Understanding the process of BCP
differentiation requires an integrated approach of single-cell
DNA, RNA and protein analysis, which can be applied
for studying blockades in BCP differentiation pathways of
genetically defined immunodeficient patients. We propose
that our immunophenotyping panel can be used in multi-
center studies with the standardization stringency developed
by the EuroFlow consortium (26), thus allowing to mutually
compare the data-files generated on patients with primary
immunodeficiency with those of individuals with undisturbed B
cell development.
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